Calcium sensitizer levosimendan and piperphentonamne: Research advances

Journal of International Pharmaceutical Research

Volumn 37, Issue 1, 2010, Pages 32-35

  Yang, Xiang Yang ^a   Li, Ruo Bing ^b   Wan, Hua Yin ^c  

^a Affiliated Outpatient Department of Guangzhou Military Region   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Guangzhou Zhongwen Biotechnology Co Ltd   (China)

Author keywords

Calcium sensitizer; Cardioprotection; Cardiotonic; Clinical trial; Levosimendan; Piperphentonamine

Indexed keywords

CALCIUM SENSITIZER; DIGOXIGENIN; LEVOSIMENDAN; PIPERPHENTONAMINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART SURGERY; HUMAN; REPERFUSION INJURY;

EID: 77952825884     PISSN: 16740440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parissis JT, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart [J]. Expert Opin Invest Drugs, 2008, 17(8):1143-1150.
2. Antoniades C, Tousoulis D, Koumallos N, et al. Levosimendan: beyond its simple inotropic effect in heart failure [J]. Pharmacol Ther, 2007, 114(2):184-197. (Pubitemid 46561532)
3. Pinto BB, Rehberg S, Ertmer C, et al. Role of levosimendan in sepsis and septic shock [J]. Curr Opin Anaesthesiol, 2008, 21 (2):168-177.
4. Lehtonen L, Põder P. The utility of levosimendan in the treatment of heart failure [J]. Ann Med, 2007, 39(1):2-17. (Pubitemid 46272633)
5. Archan S, Toller W. Levosimendan: current status and future prospects[J]. Curr Opin Anaesthesiol, 2008, 21(1):78-84.
6. Kota B, Prasad AS, Economides C, et al. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: mpact on heart failure [J]. J Cardiovasc Pharmacol Ther, 2008, 13(4):269-278.
7. Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan n clinical practice [J]. Rev Port Cardiol, 2009, 28(2):143-154.
8. Duygu H, Nalbantgil S, Zoghi M, et al. Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis [J]. Clin Cardiol, 2009, 32(4):187-192.
9. Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure [J]. Heart Vessels, 2009, 24(1):16-21.
10. Mebazaa A, Nieminen MS. Levosimendan vs dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE[J]. Eur J Heart Fail, 2009, 11(3):304-311.
11. Duygu H, Nalbantgil S, Ozerkan F, et al. Effects of levosimendan on left atrial functions in patients with schemic heart failure [J]. Clin Cardiol, 2008, 31(12):607-613.
12. Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure-the PERSIST study [J]. Eur J Heart Fail, 2008, 10(12):1246-1254.
13. Harjola VP, Oikarinen L. The hemodynamic and pharmacokinetc interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure [J]. Int J Clin Pharmacol Ther, 2008, 46(8):389-399.
14. Duygu H, Turk U, Ozdogan O, et al. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol [J]. Cardiovasc Ther, 2008, 26(3):182-188.
15. Tagarakis GI, Tsilimingas NB. Levosimendan for heart-operated patients: what is the state of the art? [J]. Recent Pat Cardiovasc Drug Discov, 2009, 4(1):22-24.
16. Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with mpaired left ventricular function [J]. Ann Thorac Surg, 2009, 87(2):448-454.
17. Tritapepe L, De Santis V. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery[J]. Br J Anaesth, 2009, 102(2):198-204.
18. De Hert SG, Lorsomradee S, van den Eede H, et al. A randomized trial evaluating different modalities of levosimendan adminstration in cardiac surgery patients with myocardial dysfunction [J]. J Cardiothorac Vasc Anesth, 2008, 22(5):699-705.
19. Järvelä K, Maaranen P, Sisto T, et al. Levosimendan in aortic valve surgery: cardiac performance and recovery [J]. J Cardiothorac Vasc Anesth, 2008, 22(5):693-698.
20. Sterba M, Banerjee A, Mudaliar Y. Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients [J]. Crit Care Resusc, 2008, 10(3):182-186.
21. Garcia-Gonzalez MJ, Dominguez-Rodriguez A. New pharmacologic options in the treatment of acute coronary syndromes and myocardial ischemia-reperfusion injury: potential role of levosimendan[J]. Minerva Cardioangiol, 2007, 55(5):625-635. (Pubitemid 350205682)
22. Cianfrocca C, Pelliccia F, Pasceri V, et al. Strain rate analysis and levosimendan improve detection of myocardial viability by dobutamine echocardiography in patients with post-infarction eft ventricular dysfunction: a pilot study [J]. J Am Soc Echocardiogr, 2008, 21(9):1068-1074.
23. Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan s superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction[J]. Crit Care Med, 2008, 36 (8):2257-2266.
24. [EB/OL]. (2008-01-08) [2009-08-01]. http://zq. gdda. gov.cn/sofpro/cms/ previewjspfile/gdfda/cms -0000000000000000140-tpl.jsp? requestCode -65657&CategoryID=165.
25. [EB/OL]. (2009-07-28) [2009-08-01]. http://www.chemdrug.com/tradeinfo/ offerdetail/1-3-0-7254.html.
26. (PPTA) [EB/OL]. (2004-06-30) [2009-08-01]. http://www.gzkjcg.gov. cn/Default. aspx? tabid=183&ItemId=877&returnTabId.